THE IMPROVING IMMUNOLOGICAL EFFICACY OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HIV-INFECTED PATIENTS BY ENTEROSORBTION

Abstract

SUMMARY. The aim of study was to evaluate the effect of
combined use HAART and silicon-organic enterosorbent
«Atoxil» on the dynamics of immunological parameters
in patients with HIV infection. The study included
39 patients with IV clinical stage of HIV infection who
were randomized into two groups: the first group –
19 patients who received HAART and enterosorbent
«Atoxil» , the second – 20 patients who received HAART
alone. The average count of CD4-lymphocytes was
79 (14-270) in the first group and 87 (51-205) in the
second. In 93 % of patients have been opportunistic and
AIDS-defining diseases, including tuberculosis prevailed
(80 %). All the patients were received HAART – AZT +
3TC + EFV. After 6 months of treatment, the level of
HIV-RNA-1 was not detected in 95 % of patients in both
groups. In the first group the absolute amount of CD4-
lymphocytes in 6 months of HAART increased to 201
(179-302), and was greater (P<0.05) than in the second
group (159 (52-198)). Thus, after 6 months of HAART
in the first group of patients who additionally received
enterosorbent, the average increase in the number of
CD4-lymphocyte count was 70 % higher than in the
second group, which received only HAART, with the
same virological efficacy of antiviral treatment.
Key words: HIV infection, enterosorbent, HAART, CD4
cell, microbial translocation, immune activation